Drug related crisis in myasthenia gravis

Journal of Association of Physicians of India

Volumn 54, Issue OCT., 2006, Pages 820-821

  Rajasekaran, D ^a   Chandrasekar, S ^a   Rajendran, M ^a  

^a STANLEY MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALE; MYASTHENIA GRAVIS;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; HUMANS; MALE; MYASTHENIA GRAVIS; NIFEDIPINE;

EID: 33749863766     PISSN: 00045772     EISSN: 00045772     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Ann-M- Mc Namara: David RP Guay, et al. American Society of Consultant Pharmacist. Consult Pharm 1997;12:155-64.
2. Swash M, Ingram DA, et al. Adverse effects of Verapamil in myasthenia gravis. Muscle Nerve 1992;15:396-8.
3. Nogues MA River o A, et al. Arterial hypertension, nifedipine and myasthenia gravis. Muscle Nerve 1993;16:797.
4. Swash M, et al. Arterial hypertension, nifedipine and myasthenia gravis. Muscle Nerve 1993;16:797.
5. Adam LP, Henderson EG, et al. Calcium channel effects are potent non-competitive blockers of acetylcholine receptor. European Journal of Physiology 1990;416:586-93.
6. Pina latorre MA, Cobeta JC, et al. Journal of clinical Pharmacology and Therapeutics 1998;23:399-401.